Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Optic nerve diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Optic nerve diseases. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2020-005264-60 Sponsor Protocol Number: CHF6467-OPG Start Date*: 2021-11-26
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT)
    Medical condition: Optic pathway glioma - optic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073338 Optic glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016982-26 Sponsor Protocol Number: ST200-ODU-09-01 Start Date*: 2010-11-04
    Sponsor Name:SIGMA-TAU
    Full Title: Neuronal conduction along the visual patways after oral treatment with Acetyl-L-carnitine in patients with Leber’s Hereditary Optic Neuropathy
    Medical condition: Leber’s Hereditary Optic Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061323 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002303-14 Sponsor Protocol Number: A5951110 Start Date*: 2008-12-17
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA
    Full Title: PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER
    Medical condition: This study is designed to understand the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for two months or longer for the developmen...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10061323 Optic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002679-42 Sponsor Protocol Number: SNT-II-003 Start Date*: 2006-11-22
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy
    Medical condition: Leber's Hereditary Optic Neuropathy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002628-34 Sponsor Protocol Number: thorp8617-1 Start Date*: 2012-08-29
    Sponsor Name:Thor Petersen
    Full Title: Optic neuritis and early treatment with methylprednisolone.
    Medical condition: Optic neuritis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10030946 Optic neuritis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003030-14 Sponsor Protocol Number: 758/11 Start Date*: 2012-09-03
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Nerve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas.
    Medical condition: Glioma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030953 Optic tract glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003475-11 Sponsor Protocol Number: UCL/11/0083 Start Date*: 2011-11-15
    Sponsor Name:University College London (UCL)
    Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
    Medical condition: Acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004980-39 Sponsor Protocol Number: Amiloride02 Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005113-39 Sponsor Protocol Number: SSP-2 Start Date*: 2013-04-08
    Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis
    Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001493-28 Sponsor Protocol Number: OPA1 Start Date*: 2020-09-24
    Sponsor Name:Medizinische Universität Graz, Univ.-Augenklinik
    Full Title: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation
    Medical condition: Autosomal dominant optic atrophy (ADOA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019895 Hereditary optic atrophy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003925-26 Sponsor Protocol Number: 28156 Start Date*: 2008-01-24
    Sponsor Name:Merck Serono International S.A.
    Full Title: Estudio aleatorizado, multicéntrico, doble ciego, de dos ramas y controlado frente a placebo para evaluar la seguridad y la tolerabilidad, y para explorar el efecto neuroprotector de atacicept eva...
    Medical condition: Neuritis óptica Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001405-90 Sponsor Protocol Number: GS-LHON/CLIN/01 Start Date*: 2013-12-26
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002968-27 Sponsor Protocol Number: CFTY720D2402 Start Date*: 2013-01-29
    Sponsor Name:Novartis Farmaceutica, S.A
    Full Title: A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fing...
    Medical condition: acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006291-39 Sponsor Protocol Number: 215ON201 Start Date*: 2012-10-15
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neur...
    Medical condition: Acute Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003618-26 Sponsor Protocol Number: 215ON203 Start Date*: 2016-04-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201
    Medical condition: Acute Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) ES (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002187-40 Sponsor Protocol Number: GS-LHON-CLIN-05 Start Date*: 2018-03-15
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for U...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002153-11 Sponsor Protocol Number: GS-LHON-CLIN-06 Start Date*: 2018-02-12
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002112-27 Sponsor Protocol Number: MD1003CT2013-01MS-ON Start Date*: Information not available in EudraCT
    Sponsor Name:MEDDAY SAS
    Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study
    Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    18.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-002515-10 Sponsor Protocol Number: P000053 Start Date*: 2014-07-18
    Sponsor Name:University Medical Center Freiburg
    Full Title: Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004807-10 Sponsor Protocol Number: inims-004 Start Date*: 2013-07-17
    Sponsor Name:University Medical Center Hamburg Eppendorf
    Full Title: Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuri...
    Medical condition: MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting v...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10070425 Multiple sclerosis exacerbation LLT
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 00:32:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA